Hims & Hers Health is under federal investigation and lawsuit for alleged deceptive billing, difficult subscription cancellations, and unauthorized sharing of health data with advertisers. Barclays lowered its price target from $39 to $35, reflecting increased legal risks. The company denies wrongdoing and plans to defend itself vigorously. Separate law firms are also probing potential securities-law violations and fiduciary breaches, adding to regulatory pressure on the telehealth firm.
Hims & Hers Health has experienced a significant surge in international revenue, growing over 17-fold year-over-year to $131 million, driven by its acquisition of Eucalyptus and expansion into new markets. The company aims to exceed $600 million in i...
Berger Montague PC has initiated an investigation into Hims & Hers Health, Inc.'s Board of Directors over potential breaches of fiduciary duties. The probe focuses on allegations that the company improperly shared private user health data with advert...
Hims & Hers Health, Inc. is under investigation after the FTC sued the company for allegedly sharing customers' medical information with third-party advertisers like Snap and Meta Platforms. The lawsuit accuses Hims & Hers of deceptive and unlawful p...
